Xenon Pharmaceuticals (XENE)
(Real Time Quote from BATS)
$38.54 USD
-0.39 (-1.00%)
Updated Sep 25, 2024 01:34 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XENE 38.54 -0.39(-1.00%)
Will XENE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Other News for XENE
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
RBC Capital Sticks to Its Buy Rating for Xenon (XENE)
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
Xenon Pharmaceuticals Appoints New COO